Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,247 INR | +1.23% | +1.61% | +0.85% |
16/04 | Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak | CI |
28/03 | Alkem Laboratories Forms Subsidiary for Medical Devices Business | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 34.27 and 29.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.71 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.85% | 742.12Cr | C- | ||
+31.37% | 59TCr | B | ||
-2.60% | 36TCr | C+ | ||
+20.83% | 33TCr | B- | ||
+5.69% | 29TCr | C+ | ||
+14.83% | 24TCr | B+ | ||
+9.93% | 21TCr | B- | ||
-6.95% | 20TCr | A+ | ||
+10.77% | 17TCr | C+ | ||
+0.10% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALKEM Stock
- Ratings Alkem Laboratories Limited